Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

▤ Summary

Boundless Bio and Serapha Bio have entered into a definitive all-stock merger agreement. The combined company will operate as Serapha Bio and plans to trade on Nasdaq under the ticker AATD. Serapha also secured about $230 million in private placement commitments to support the transaction and fund development of SERP-01. The company will use the capital to advance its base-editing therapy for severe alpha-1 antitrypsin deficiency through mid- and late-stage clinical milestones. The deal gives Serapha a public-market platform and long runway to continue development.

▦ Linked Companies